|
Feb 13
|
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
|
|
Feb 13
|
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
|
|
Feb 13
|
Sanofi to take $250M charge on study failure for E. coli vaccine
|
|
Feb 13
|
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
|
|
Feb 12
|
Sanofi (SNY): Among the Best International Dividend Stocks to Buy Now
|
|
Feb 3
|
L’Oreal Sells €3 Billion of Sanofi Stock Back to Drugmaker
|
|
Feb 3
|
Press Release: Sanofi announces buy back of shares from L’Oréal
|
|
Jan 31
|
Sanofi reports Q4 2024 increase in net income to $916m
|
|
Jan 31
|
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
|
|
Jan 31
|
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
|
|
Jan 31
|
Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...
|
|
Jan 31
|
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
|
|
Jan 30
|
Sanofi (SNY) Q4 2024 Earnings Call Transcript
|
|
Jan 30
|
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
|
|
Jan 30
|
Sanofi: Q4 Earnings Snapshot
|
|
Jan 30
|
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
|
|
Jan 30
|
Sanofi forecasts stronger profit growth, announces €5 billion stock buyback
|
|
Jan 30
|
Sanofi plans share buybacks, signals more deals post Opella sale
|
|
Jan 30
|
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
|
|
Jan 29
|
Sanofi: Information concerning the total number of voting rights and shares - December 2024
|